| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 24.0K | 1.1% | 6.8% |
| Total Income | 24.0K | 1.1% | 6.8% |
| Expenditure | 16.5K | 4.4% | 13.8% |
| PBT | 7.5K | 15.4% | 124.5% |
| Net Profit | 5.2K | 7.0% | 91.2% |
| OPM | — | ||
| NPM | 21.47% | 1.85pp | 9.48pp |
| EPS | 2.14 | 7.0% | 91.1% |
Johnson & Johnson Announces Q3 2025 Sales and Earnings; Plans Orthopaedics Business Separation
30 Mar 2026 · 30 Mar, 3:57 am
Summary
Johnson & Johnson announced its sales and earnings for the third quarter ended September 28, 2025. The company also announced its intent to separate the Company's Orthopaedics business.
Key Highlights
- 1
Sales and earnings for Q3 2025 were announced
- 2
Intent to separate the Orthopaedics business was announced
Informational and educational content only. Not investment advice.